marstacimab-hncq 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5839 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • marstacimab
  • marstacimab-hncq
  • hympavzi
  • PF-06741086
Marstacimab-hncq is a human IgG1 monoclonal antibody that binds to the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI). Binding of marstacimab to TFPI inhibits TFPI activity and enhances tissue factor-mediated thrombin generation, ehancing coagulation.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Oct. 11, 2024 FDA Pfizer Inc.
Dec. 27, 2024 PMDA Pfizer Japan Inc.
Nov. 18, 2024 EMA Pfizer Europe MA EEIG

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02BX11 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Other systemic hemostatics

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs
avatrombopagcarbazochromeconcizumabeltrombopagemicizumabetamsylatefitusiranfostamatiniblusutrombopagromiplostim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Reduce the frequency of bleeding episodes in patients with hemophilia A or B indication 90935002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tissue factor pathway inhibitor Secreted INHIBITOR Kd 8.58 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL3990039 ChEMBL_ID
C000656192 MESH_SUPPLEMENTAL_RECORD_UI
4043525 VANDF
4043526 VANDF
C5965553 UMLSCUI
CHEBI:756519 CHEBI
1985638-39-8 SECONDARY_CAS_RN
43434 MMSL
d10232 MMSL
13403 IUPHAR_LIGAND_ID
10789 INN_ID
2697132 RXNORM
D11261 KEGG_DRUG
0UB3OA67O7 UNII
019893 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
HYMPAVZI HUMAN PRESCRIPTION DRUG LABEL 1 0069-0775 INJECTION, SOLUTION 75 mg SUBCUTANEOUS BLA 32 sections
HYMPAVZI HUMAN PRESCRIPTION DRUG LABEL 1 0069-1510 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 32 sections
HYMPAVZI HUMAN PRESCRIPTION DRUG LABEL 1 0069-1575 INJECTION, SOLUTION 75 mg SUBCUTANEOUS BLA 32 sections
HYMPAVZI HUMAN PRESCRIPTION DRUG LABEL 1 0069-2151 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 32 sections
HYMPAVZI HUMAN PRESCRIPTION DRUG LABEL 1 0069-2151 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 32 sections